Infection Risk and Safety of Corticosteroid Use

Svensson, 2005, Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial, Arthritis Rheum, 52, 3360, 10.1002/art.21298

Wassenberg, 2005, Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicenter, double-blind, placebo-controlled trial, Arthritis Rheum, 52, 3371, 10.1002/art.21421

Duru, 2013, EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases, Ann Rheum Dis, 72, 1905, 10.1136/annrheumdis-2013-203249

Lukert, 1990, Glucocorticoid-induced osteoporosis: pathogenesis and management, Ann Intern Med, 112, 352, 10.7326/0003-4819-112-5-352

Clore, 2009, Glucocorticoid-induced hyperglycemia, Endocr Pract, 15, 469, 10.4158/EP08331.RAR

Kersey, 2006, Corticosteroid-induced glaucoma: a review of the literature, Eye (Lond), 20, 407, 10.1038/sj.eye.6701895

Walker, 2007, Glucocorticoids and cardiovascular disease, Eur J Endocrinol, 157, 545, 10.1530/EJE-07-0455

Powell, 2010, Steroid induced osteonecrosis: an analysis of steroid dosing risk, Autoimmun Rev, 9, 721, 10.1016/j.autrev.2010.06.007

Weinstein, 2012, Glucocorticoid-induced osteonecrosis, Endocrine, 41, 183, 10.1007/s12020-011-9580-0

McEwen, 1997, The role of adrenocorticoids as modulators of immune function in health and disease: neural, endocrine and immune interactions, Brain Res Brain Res Rev, 23, 79, 10.1016/S0165-0173(96)00012-4

Boumpas, 1993, Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates, Ann Intern Med, 119, 1198, 10.7326/0003-4819-119-12-199312150-00007

Coutinho, 2011, The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights, Mol Cell Endocrinol, 335, 2, 10.1016/j.mce.2010.04.005

Purton, 2004, Expression of the glucocorticoid receptor from the 1A promoter correlates with T lymphocyte sensitivity to glucocorticoid-induced cell death, J Immunol, 173, 3816, 10.4049/jimmunol.173.6.3816

Smitten, 2008, The risk of hospitalized infection in patients with rheumatoid arthritis, J Rheumatol, 35, 387

Doran, 2002, Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study, Arthritis Rheum, 46, 2287, 10.1002/art.10524

Goldenberg, 1989, Infectious arthritis complicating rheumatoid arthritis and other chronic rheumatic disorders, Arthritis Rheum, 32, 496, 10.1002/anr.1780320422

Bermas, 1994, T helper cell dysfunction in systemic lupus erythematosus (SLE): relation to disease activity, J Clin Immunol, 14, 169, 10.1007/BF01533366

Marquart, 1995, Complement receptor expression and activation of the complement cascade on B lymphocytes from patients with systemic lupus erythematosus (SLE), Clin Exp Immunol, 101, 60, 10.1111/j.1365-2249.1995.tb02277.x

Tektonidou, 2015, Burden of serious infections in adults with systemic lupus erythematosus. A national population-based study, 1996-2011, Arthritis Care Res (Hoboken), 67, 1078, 10.1002/acr.22575

Dixon, 2011, The association between systemic glucocorticoid therapy and the risk of infection in patients with rheumatoid arthritis: systematic review and meta-analyses, Arthritis Res Ther, 13, R139, 10.1186/ar3453

Capell, 2004, Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: results of a randomised controlled trial, Ann Rheum Dis, 63, 797, 10.1136/ard.2003.014050

Choy, 2008, Factorial randomised controlled trial of glucocorticoids and combination disease modifying drugs in early rheumatoid arthritis, Ann Rheum Dis, 67, 656, 10.1136/ard.2007.076299

Durez, 2007, Treatment of early rheumatoid arthritis: a randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolone, Arthritis Rheum, 56, 3919, 10.1002/art.23055

Gerlag, 2004, Effects of oral prednisolone on biomarkers in synovial tissue and clinical improvement in rheumatoid arthritis, Arthritis Rheum, 50, 3783, 10.1002/art.20664

Kirwan, 2004, A randomised placebo controlled 12 week trial of budesonide and prednisolone in rheumatoid arthritis, Ann Rheum Dis, 63, 688, 10.1136/ard.2003.008573

Sheldon, 2003, Ileum-targeted steroid therapy in rheumatoid arthritis: double-blind, placebo-controlled trial of controlled-release budesonide, Rheumatol Int, 23, 154, 10.1007/s00296-002-0278-8

van Everdingen, 2002, Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial, Ann Intern Med, 136, 1, 10.7326/0003-4819-136-1-200201010-00006

Buttgereit, 2013, Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2), Ann Rheum Dis, 72, 204, 10.1136/annrheumdis-2011-201067

Bakker, 2012, Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial, Ann Intern Med, 156, 329, 10.7326/0003-4819-156-5-201203060-00004

Grijalva, 2011, Initiation of tumor necrosis factor-alpha antagonists and the risk of hospitalization for infection in patients with autoimmune diseases, JAMA, 306, 2331, 10.1001/jama.2011.1692

Dixon, 2012, Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case-control analysis, Ann Rheum Dis, 71, 1128, 10.1136/annrheumdis-2011-200702

Wolfe, 2006, Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy, Arthritis Rheum, 54, 628, 10.1002/art.21568

Schneeweiss, 2007, Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis, Arthritis Rheum, 56, 1754, 10.1002/art.22600

Widdifield, 2013, Serious infections in a population-based cohort of 86,039 seniors with rheumatoid arthritis, Arthritis Care Res (Hoboken), 65, 353, 10.1002/acr.21812

Curtis, 2007, Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists, Arthritis Rheum, 56, 1125, 10.1002/art.22504

Strangfeld, 2011, Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?, Ann Rheum Dis, 70, 1914, 10.1136/ard.2011.151043

Franklin, 2007, Risk and predictors of infection leading to hospitalisation in a large primary-care-derived cohort of patients with inflammatory polyarthritis, Ann Rheum Dis, 66, 308, 10.1136/ard.2006.057265

Greenberg, 2010, Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry, Ann Rheum Dis, 69, 380, 10.1136/ard.2008.089276

Xie, 2012, The risk factors for nosocomial infection in chinese patients with active rheumatoid arthritis in shanghai, ISRN Rheumatol, 2012, 215692, 10.5402/2012/215692

van Dartel, 2013, Predictors for the 5-year risk of serious infections in patients with rheumatoid arthritis treated with anti-tumour necrosis factor therapy: a cohort study in the dutch rheumatoid arthritis monitoring (DREAM) registry, Rheumatology (Oxford), 52, 1052, 10.1093/rheumatology/kes413

Dirac, 2012, Environment or host?: a case-control study of risk factors for mycobacterium avium complex lung disease, Am J Respir Crit Care Med, 186, 684, 10.1164/rccm.201205-0825OC

MacDougall, 2011, Risk factors for cryptococcus gattii infection, british columbia, canada, Emerg Infect Dis, 17, 193, 10.3201/eid1702.101020

Garnacho-Montero, 2005, Isolation of aspergillus spp. from the respiratory tract in critically ill patients: risk factors, clinical presentation and outcome, Crit Care, 9, R191, 10.1186/cc3488

Dimopoulos, 2008, Candida albicans versus non-albicans intensive care unit-acquired bloodstream infections: differences in risk factors and outcome, Anesth Analg, 106, 523, 10.1213/ane.0b013e3181607262

Yale, 1996, Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy, Mayo Clin Proc, 71, 5, 10.4065/71.1.5

Lertnawapan, 2009, Risk factors of pneumocystis jeroveci pneumonia in patients with systemic lupus erythematosus, Rheumatol Int, 29, 491, 10.1007/s00296-008-0721-6

Kermani, 2011, Pneumocystis jiroveci pneumonia in giant cell arteritis: a case series, Arthritis Care Res (Hoboken), 63, 761, 10.1002/acr.20435

Chew, 2015, Pneumocystis jirovecii pneumonia in patients with autoimmune disease on high-dose glucocorticoid, J Clin Rheumatol, 21, 72, 10.1097/RHU.0000000000000215

Mekinian, 2011, Pneumocystis jirovecii colonization in patients with systemic autoimmune diseases: prevalence, risk factors of colonization and outcome, Rheumatology (Oxford), 50, 569, 10.1093/rheumatology/keq314

Fritzsche, 2012, High prevalence of pneumocystis jirovecii colonization among patients with autoimmune inflammatory diseases and corticosteroid therapy, Scand J Rheumatol, 41, 208, 10.3109/03009742.2011.630328

Jarrousse, 1993, Increased risk of pneumocystis carinii pneumonia in patients with wegener's granulomatosis, Clin Exp Rheumatol, 11, 615

Kronbichler, 2015, Frequency, risk factors and prophylaxis of infection in ANCA-associated vasculitis, Eur J Clin Invest, 45, 346, 10.1111/eci.12410

Ognibene, 1995, Pneumocystis carinii pneumonia: a major complication of immunosuppressive therapy in patients with wegener's granulomatosis, Am J Respir Crit Care Med, 151, 795

Guillevin, 1997, A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized wegener's granulomatosis, Arthritis Rheum, 40, 2187, 10.1002/art.1780401213

Besada, 2013, Should pneumocystis jiroveci prophylaxis be recommended with rituximab treatment in ANCA-associated vasculitis?, Clin Rheumatol, 32, 1677, 10.1007/s10067-013-2293-4

Godeau, 1995, Factors associated with pneumocystis carinii pneumonia in wegener's granulomatosis, Ann Rheum Dis, 54, 991, 10.1136/ard.54.12.991

Veetil, 2013, Incidence and time trends of herpes zoster in rheumatoid arthritis: a population-based cohort study, Arthritis Care Res (Hoboken), 65, 854, 10.1002/acr.21928

Wolfe, 2006, Rates and predictors of herpes zoster in patients with rheumatoid arthritis and non-inflammatory musculoskeletal disorders, Rheumatology (Oxford), 45, 1370, 10.1093/rheumatology/kel328

Strangfeld, 2009, Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents, JAMA, 301, 737, 10.1001/jama.2009.146

Winthrop, 2013, Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster, JAMA, 309, 887, 10.1001/jama.2013.1099

Pappas, 2015, Herpes zoster reactivation in patients with rheumatoid arthritis: analysis of disease characteristics and disease modifying anti-rheumatic drugs, Arthritis Care Res (Hoboken), 10.1002/acr.22628

Zisman, 2014, Psoriatic arthritis treatment and the risk of herpes zoster, Ann Rheum Dis

Fardet, 2009, Incidence, risk factors, and severity of herpesvirus infections in a cohort of 121 patients with primary dermatomyositis and dermatomyositis associated with a malignant neoplasm, Arch Dermatol, 145, 889, 10.1001/archdermatol.2009.152

Buonfrate, 2013, Severe strongyloidiasis: a systematic review of case reports, BMC Infect Dis, 13, 78, 10.1186/1471-2334-13-78

Brassard, 2006, Antirheumatic drugs and the risk of tuberculosis, Clin Infect Dis, 43, 717, 10.1086/506935

Winthrop, 2013, Mycobacterial diseases and antitumour necrosis factor therapy in USA, Ann Rheum Dis, 72, 37, 10.1136/annrheumdis-2011-200690

Tam, 2002, Risk factors and clinical features for tuberculosis among patients with systemic lupus erythematosus in hong kong, Scand J Rheumatol, 31, 296, 10.1080/030097402760375205

Ramagopalan, 2013, Associations between selected immune-mediated diseases and tuberculosis: record-linkage studies, BMC Med, 11, 97, 10.1186/1741-7015-11-97

Jick, 2006, Glucocorticoid use, other associated factors, and the risk of tuberculosis, Arthritis Rheum, 55, 19, 10.1002/art.21705

Kim, 1998, Mycobacterium tuberculosis infection in a corticosteroid-treated rheumatic disease patient population, Clin Exp Rheumatol, 16, 9

Brassard, 2009, Rheumatoid arthritis, its treatments, and the risk of tuberculosis in quebec, canada, Arthritis Rheum, 61, 300, 10.1002/art.24476

Katsuyama, 2014, Prophylaxis for pneumocystis pneumonia in patients with rheumatoid arthritis treated with biologics, based on risk factors found in a retrospective study, Arthritis Res Ther, 16, R43, 10.1186/ar4472

Mukhtyar, 2009, EULAR recommendations for the management of primary small and medium vessel vasculitis, Ann Rheum Dis, 68, 310, 10.1136/ard.2008.088096

Davis, 2014, Prescriptions for a toxic combination: use of methotrexate plus trimethoprim-sulfamethoxazole in the united states, Southampt Med J, 107, 292

Shingles (Herpes Zoster). Centers for Disease Control and Prevention. 2014. Available at: http://www.cdc.gov/vaccines/vpd-vac/shingles/hcp-vaccination.htm. Accessed June 12, 2015.

Oxman, 2005, A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults, N Engl J Med, 352, 2271, 10.1056/NEJMoa051016

Curtis, 2014, Herpes zoster infection across auto-immune and inflammatory diseases: implications for vaccination, Ann Rheum Dis, 73, 452, 10.1136/annrheumdis-2014-eular.5983

ZOSTAVAX Zoster Vaccine Live Product Information. Available at: MerckVaccines.com. Accessed June 12, 2015.

Singh, 2012, 2012 update of the 2008 american college of rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis, Arthritis Care Res (Hoboken), 64, 625, 10.1002/acr.21641

Contraindications and Precautions to Commonly Used Vaccines in Adults. Centers for Disease Control and Prevention. 2015. Available at: http://www.cdc.gov/vaccines/schedules/hcp/imz/adult-contraindications.html. Accessed June 12, 2015.

2000, Targeted tuberculin testing and treatment of latent tuberculosis infection. American thoracic society, MMWR Recomm Rep, 49, 1

Kim, 2013, Factors influencing discrepancies between the QuantiFERON-TB gold in tube test and the tuberculin skin test in korean patients with rheumatic diseases, Semin Arthritis Rheum, 42, 424, 10.1016/j.semarthrit.2012.07.001

Arenas Miras Mdel, 2014, Diagnosis of latent tuberculosis in patients with systemic lupus erythematosus: T.SPOT.TB versus tuberculin skin test, Biomed Res Int, 2014, 291031

Matulis, 2008, Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: performance of a mycobacterium tuberculosis antigen-specific interferon gamma assay, Ann Rheum Dis, 67, 84, 10.1136/ard.2007.070789

Vassilopoulos, 2008, Usefulness of enzyme-linked immunospot assay (elispot) compared to tuberculin skin testing for latent tuberculosis screening in rheumatic patients scheduled for anti-tumor necrosis factor treatment, J Rheumatol, 35, 1271

Calabrese, 2014, Indeterminate QuantiFERON-TB gold in-tube results in patients with chronic inflammatory diseases on immunosuppressive therapy, Arthritis Care Res (Hoboken), 67, 1063, 10.1002/acr.22454

Bartalesi, 2009, QuantiFERON-TB gold and the TST are both useful for latent tuberculosis infection screening in autoimmune diseases, Eur Respir J, 33, 586, 10.1183/09031936.00107608

Recommended Adult Immunization Schedule–United States - 2015. Centers for Disease Control and Prevention. Available at: http://www.cdc.gov/vaccines/schedules/hcp/adult.html. Accessed June 12, 2015.